Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.60 |
| ▸ | MLYCD | O95822 | 12/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28253028 | 0.98 | CES1 (0.58) | CES1MLYCDPTGS1TRPV1MEN1 | |
| SCHEMBL7071706 | 0.84 | MAPT (0.54) | CES1MLYCDPTGS1MEN1PKM | |
| SCHEMBL30445738 | 0.81 | CES1 (0.60) | CES1MLYCDTRPV1POLBKMT2A | |
| SCHEMBL19056956 | 0.80 | CES1 (0.65) | CES1MLYCDTRPV1 | |
| SCHEMBL9115535 | 0.79 | LMNA (0.44) | PTGS1MEN1LMNAPOLBPKM | |
| SCHEMBL2174033 | 0.78 | CES1 (0.62) | CES1MLYCDTRPV1LMNAPKM | |
| SCHEMBL16823 | 0.78 | CES1 (0.62) | CES1MLYCDTRPV1 | |
| SCHEMBL1421656 | 0.78 | CES1 (0.70) | CES1MLYCD | |
| SCHEMBL1047383 | 0.76 | CA2 (0.67) | CES1MLYCDMEN1LMNAPKM | |
| SCHEMBL1176747 | 0.76 | LMNA (0.45) | PTGS1MEN1LMNAPOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137293-A2 | ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS | Roche Sequencing Solutions, Inc. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250188243-A1 | Healable and Recyclable Polyimide Polymer Resin, Healing Method and Recycling Method Thereof | NATIONAL TSING HUA UNIVERSITY (TW) | 2025-06-12 | — | — | US | disclosed |
| US-12252591-B2 | Healable and recyclable polyimide polymer resin, healing method and recycling method thereof | NATIONAL TSING HUA UNIVERSITY (TW) | 2025-03-18 | — | — | US | disclosed |
| US-20250026769-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-01-23 | — | — | US | disclosed |
| EP-4423081-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | The Children's Medical Center Corporation (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-113651710-B | Preparation method of 3, 5-substituted-4-amino trifluoroacetophenone and derivatives thereof | 台州臻挚生物科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240018330-A1 | Healable and Recyclable Polyimide Polymer Resin, Healing Method and Recycling Method Thereof | FENNECO TECH CO., LTD (TW) | 2024-01-18 | — | — | US | disclosed |
| CN-117402355-A | Repairable and recyclable polyimide polymer resin and repairing and recycling method thereof | 周鹤修 | 2024-01-16 | — | — | CN | disclosed |
| WO-2023086220-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086220-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-1319007-A1 | FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024702-A1 | FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-1161233-A2 | LXR MODULATORS | Tularik Inc. (US) | 2001-12-12 | — | — | EP | disclosed |
| US-6316503-B1 | LXR modulators | TULARIK INC. | 2001-11-13 | — | — | US | disclosed |
| WO-2000054759-A2 | LXR MODULATORS | TULARIK INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| WO-1998031689-A1 | NOVEL MIXED BENZENE ACID DERIVATIVES, METHOD FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | ADIR ET COMPAGNIE (FR) | 1998-07-23 | — | — | WO | disclosed |
| EP-0281829-B1 | Adducts of ketonic compounds with the anions of oxygenated acids, process for their preparation, their use and azo ketonic compounds | MOELLER WILLI AG (CH) | 1994-05-04 | — | — | EP | disclosed |
| US-5037968-A | Ion Selective Membranes Of Ion Selective Electrodes; Color Indicators | Moller, Willi (CH) | 1991-08-06 | — | — | US | disclosed |
| EP-0281829-A2 | Adducts of ketonic compounds with the anions of oxygenated acids, process for their preparation, their use and azo ketonic compounds | Willi Möller AG (CH) | 1988-09-14 | — | — | EP | disclosed |
| US-4404215-A | ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS | SCIENCE UNION ET CIE (FR) | 1983-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026769-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, PARP15, TERT | CES1 2423/4885MLYCD 908/4885PTGS1 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.